Kisspeptin for fertility: what the research actually shows

What did @lilianaroblero__ actually say?

She's using kisspeptin at 250 micrograms daily, starting on cycle day three through her LH surge, pre-filling syringes each week. Her reported benefits include steadier basal body temperature (BBT) readings during the luteal phase, reduced emotional volatility around ovulation and PMS, and a general sense of hormonal calm. She's also stacking it with GHK-Cu and another compound she refers to as "good sign on" — likely gonadorelin — for what she describes as fertility support. She plans to update on her partner's peptide protocol for male fertility in a future video.

To be clear: this is a personal account from someone pursuing fertility treatment, tagged "for research purposes only." She's not claiming to be a clinician, and she's not advising others to copy her protocol. That matters when evaluating the rest of this.

Does the science back this up?

Partly, and more than you might expect for a TikTok peptide video. Kisspeptin is not a fringe compound — it's a legitimate subject of clinical fertility research, particularly in the UK.

Kisspeptin (encoded by the KISS1 gene) is a neuropeptide that directly stimulates GnRH neurons, which then drive LH and FSH release. It sits upstream of the entire reproductive hormone cascade. Jayasena et al. (2014, Journal of Clinical Endocrinology and Metabolism) demonstrated that kisspeptin-54 infusion triggered LH surges in women with hypothalamic amenorrhea. Skorupskaite et al. (2014, Human Reproduction Update) reviewed its central role in reproductive neuroendocrinology, confirming kisspeptin's position as a key regulator of the hypothalamic-pituitary-gonadal axis. More clinically relevant: Abbara et al. (2020, Nature Communications) showed kisspeptin administration could restore LH pulsatility in women with functional hypothalamic amenorrhea.

What's less clear is whether exogenous kisspeptin self-administered subcutaneously — at a fixed daily dose, outside a clinical trial — produces the same effects she's describing. The trials used IV infusion or precisely timed subcutaneous doses under controlled monitoring. That gap between research context and personal protocol is significant.

What did they get wrong (or right)?

The BBT observation is actually the most scientifically interesting part of this video, and she deserves credit for tracking it systematically. A sustained, elevated luteal phase BBT is a reasonable proxy for progesterone adequacy. If kisspeptin is improving LH pulsatility in her luteal phase, downstream progesterone production could plausibly follow. That's not a wild claim — it's mechanistically coherent.

What's harder to evaluate is her attribution of emotional regulation to kisspeptin specifically. She says she's "not as hormonal, not as angry, not as frustrated." Those are real experiences. But she's also stacking GHK-Cu, and possibly another compound. Isolating kisspeptin as the cause of mood stabilization from a multi-compound protocol is not something she — or anyone without a controlled study — can do. She doesn't claim to, to her credit, but the framing implies it.

The dosing protocol she describes — 250 micrograms daily from cycle day three to LH surge — does not match any published clinical trial design. That's not automatically wrong, but it's not validated either. Self-dosing a neuropeptide that directly drives GnRH pulsatility without hormonal monitoring is genuinely risky. If kisspeptin overshoots LH stimulation, it can paradoxically suppress the axis, a phenomenon documented in animal models and referenced in Roa et al. (2008, Endocrinology).

What should you actually know?

Kisspeptin is real, researched, and physiologically interesting. But the distance between a clinical trial and a pre-filled syringe on TikTok is enormous, and that distance carries real risk.

Here's what the evidence actually supports: kisspeptin has a documented role in reproductive hormone signaling. It has been studied in human subjects for conditions like hypothalamic amenorrhea and IVF triggering (Abbara et al., 2020). It is not approved by the FDA for any fertility indication. It is not available as a licensed pharmaceutical in the US. What circulates in the peptide market is compounded or gray-market kisspeptin of unverified purity and concentration.

For someone with PCOS or secondary infertility, the hormonal picture is already complex. Adding an unmonitored GnRH-axis stimulant without concurrent hormone panels, ultrasound monitoring, or physician oversight is not the same as participating in a clinical trial. The positive experiences she's describing may be real. They may also be placebo effect, natural cycle variation, or effects from other compounds in her stack. Without baseline labs and a controlled protocol, there is no way to know.

If you are pursuing fertility treatment and curious about kisspeptin, the conversation to have is with a reproductive endocrinologist who follows the emerging literature, not a peptide supplier.